AltheaDx is Bringing Theranostics into Clinical Use.

Our proprietary gene expression profiles include assays for differential diagnosis of pediatric cancers and for improved diagnosis and management of prostate cancer. We have a track record of reducing the time, risk, and cost of drug development by providing biomarker discovery and development to biopharma clients and clinical testing services to physicians.

AltheaDx is located in a 20,000 sq. ft. building and operates laboratory service operations for biopharma customers in compliance with GLP requirements. CLIA certification is in process. The company has several key patents and technology affiliations with a variety of industry and academic institutions, including: NIH, NCI, UCSD, Sidney Kimmel Cancer Center, MD Anderson, and Memorial Sloan Kettering.

AltheaDx has a team of superb scientists led by an executive group with in-depth experience in lab services, product development and commercialization. The management team has a proven record of business success. The Board of Directors of AltheaDx includes industry leaders François Ferré and Magda Marquet, and representatives from the investment firm Telegraph Hill Partners.